BNP Paribas Financial Markets’s Akcea Therapeutics Inc AKCA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | – | Sell |
-5,757
| Closed | -$104K | – | 4279 |
|
|
2020
Q3 | $104K | Buy |
5,757
+2,427
| +73% | +$34.4K | ﹤0.01% | 3093 |
|
|
2020
Q2 | $45.6K | Sell |
3,330
-4,562
| -58% | -$70.4K | ﹤0.01% | 3070 |
|
|
2020
Q1 | $113K | Buy |
7,892
+5,957
| +308% | +$97.8K | ﹤0.01% | 3141 |
|
|
2019
Q4 | $32.8K | Sell |
1,935
-672
| -26% | -$12.5K | ﹤0.01% | 3854 |
|
|
2019
Q3 | $40.1K | Buy |
2,607
+616
| +31% | +$13.1K | ﹤0.01% | 3602 |
|
|
2019
Q2 | $46.7K | Sell |
1,991
-1,174
| -37% | -$29K | ﹤0.01% | 3459 |
|
|
2019
Q1 | $89.7K | Buy |
3,165
+2,829
| +842% | +$82.4K | ﹤0.01% | 3185 |
|
|
2018
Q4 | $10.1K | Sell |
336
-405
| -55% | -$11.4K | ﹤0.01% | 3344 |
|
|
2018
Q3 | $25.9K | Buy |
741
+56
| +8% | +$1.7K | ﹤0.01% | 3311 |
|
|
2018
Q2 | $16.2K | Sell |
685
-2,748
| -80% | -$65.6K | ﹤0.01% | 3577 |
|
|
2018
Q1 | $87.9K | Buy |
3,433
+60
| +2% | +$1.29K | ﹤0.01% | 3254 |
|
|
2017
Q4 | $58.6K | Buy |
3,373
+2,479
| +277% | +$48.6K | ﹤0.01% | 3579 |
|
|
2017
Q3 | $24.7K | Buy |
+894
| New | +$16.5K | ﹤0.01% | 3489 |
|
BNP Paribas Financial Markets's AKCA Position: Q4 2020 in Review
BNP Paribas Financial Markets sold out of Akcea Therapeutics Inc (AKCA) in Q4 2020, closing a stake of 5,757 shares — an estimated $104K sold.
BNP Paribas Financial Markets first reported a position in AKCA in Q3 2017 and held it in 13 quarters. The position peaked at $113K in Q1 2020. 0 funds tracked by Wall St. Rank hold AKCA as of Q4 2020.
- BNP Paribas Financial Markets reported no remaining Akcea Therapeutics Inc position as of Q4 2020 after selling out during the quarter.
- BNP Paribas Financial Markets sold 5,757 Akcea Therapeutics Inc shares in Q4 2020, an estimated $104K.
- BNP Paribas Financial Markets first reported a position in Akcea Therapeutics Inc in Q3 2017 and held it in 13 quarters.
- BNP Paribas Financial Markets's Akcea Therapeutics Inc position peaked at $113K in Q1 2020.
- 0 funds tracked by Wall St. Rank held Akcea Therapeutics Inc as of Q4 2020.
Based on BNP Paribas Financial Markets's 13F filing for Q4 2020, filed 10 Feb 2021.